IGM Biosciences, Inc.

Sanofi has taken another step on the path to becoming the world’s leading immunology company by paying $600m to acquire Dren Bio’s DR-0201, an early-stage bispecific myeloid cell engager. The French f

In September, IGM Biosciences decided to pivot into autoimmune diseases after failure in oncology, but the strategy has already foundered. The company has halted development of its two lead candidat

The market for initial public offerings in the US heated up in September with five biopharmaceutical companies launching IPOs, the second busiest month for first-time offerings in 2024 after there wer

Sanofi 's shifting of R&D resources away from cancer to cement its industry leadership in immunology and inflammation is a sensible move but the company will continue to advance some interesting early